Sami Corwin
Stock Analyst at William Blair
(n/a)
# 4,397
Out of 4,749 analysts
9
Total ratings
n/a
Success rate
-42.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sami Corwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRGX CARGO Therapeutics | Downgrades: Market Perform | n/a | $3.60 | - | 2 | Jan 30, 2025 | |
| APLT Applied Therapeutics | Downgrades: Market Perform | n/a | $0.59 | - | 1 | Dec 23, 2024 | |
| TNYA Tenaya Therapeutics | Initiates: Outperform | n/a | $1.06 | - | 1 | Jun 10, 2024 | |
| NGNE Neurogene | Initiates: Outperform | n/a | $15.85 | - | 1 | Mar 21, 2024 | |
| MESO Mesoblast | Downgrades: Market Perform | n/a | $20.14 | - | 1 | Aug 4, 2023 | |
| CRSP CRISPR Therapeutics AG | Reinstates: Outperform | $75 | $41.59 | +80.33% | 1 | May 30, 2023 | |
| LEGN Legend Biotech | Initiates: Market Perform | n/a | $38.10 | - | 1 | May 25, 2023 | |
| QURE uniQure | Initiates: Outperform | $66 | $15.74 | +319.31% | 1 | Oct 27, 2021 |
CARGO Therapeutics
Jan 30, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $3.60
Upside: -
Applied Therapeutics
Dec 23, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.59
Upside: -
Tenaya Therapeutics
Jun 10, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.06
Upside: -
Neurogene
Mar 21, 2024
Initiates: Outperform
Price Target: n/a
Current: $15.85
Upside: -
Mesoblast
Aug 4, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $20.14
Upside: -
CRISPR Therapeutics AG
May 30, 2023
Reinstates: Outperform
Price Target: $75
Current: $41.59
Upside: +80.33%
Legend Biotech
May 25, 2023
Initiates: Market Perform
Price Target: n/a
Current: $38.10
Upside: -
uniQure
Oct 27, 2021
Initiates: Outperform
Price Target: $66
Current: $15.74
Upside: +319.31%